Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01KNA
|
|||
| Former ID |
DIB001070
|
|||
| Drug Name |
Diamyd
|
|||
| Synonyms |
Oramyd; Human glutamate decarboxylase 65 kDa isoform; RhGAD-65; GAD65 (diabetes), Biosyn; GAD65 (diabetes), Diamyd; GAD65 (diabetes), OMJPI; GAD65 antigen-based therapy (diabetes), Johnson and Johnson; GAD65 (diabetes), Ortho-McNeil-Janssen Pharmaceuticals
Click to Show/Hide
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Phase 3 | [1] | |
| Company |
Diamyd medical
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glutamate decarboxylase 2 (GAD2) | Target Info | Immunomodulator | [1], [2] |
| BioCyc | Glutamate dependent acid resistance | |||
| GABA shunt | ||||
| KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
| beta-Alanine metabolism | ||||
| Taurine and hypotaurine metabolism | ||||
| Butanoate metabolism | ||||
| Metabolic pathways | ||||
| GABAergic synapse | ||||
| Type I diabetes mellitus | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Gamma-aminobutyric acid synthesis | |||
| WikiPathways | Biogenic Amine Synthesis | |||
| GABA synthesis, release, reuptake and degradation | ||||
| Alanine and aspartate metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00751842) A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Diamyd Medical. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.